Furthermore, we can show that PD-L1 may be an efficient predictive biomarker in metastatic bladder cancer patients for chemotherapy resistance, as already described by Zhang et al (2016) in non-small-cell lung cancer patients undergoing cisplatin-based neoadjuvant chemotherapy [41]. Here, CD274 is linked to non-small cell lung carcinoma.